Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 4.69B 4.05B 3.73B 3.5B 6.55B 446B 6.65B 44.09B 17.19B 217B 17.61B 17.23B 752B P/E Ratio 2026 *
12.1x
P/E Ratio 2027 * 11.2x
Enterprise Value 4.75B 4.1B 3.78B 3.54B 6.63B 451B 6.73B 44.6B 17.39B 220B 17.81B 17.43B 760B EV / Sales 2026 *
3.77x
EV / Sales 2027 * 3.33x
Free-Float
94.9%
Yield 2026 *
-
Yield 2027 * -
1 day+0.92%
1 week+2.30%
Current month+6.83%
1 month+0.52%
3 months+24.69%
6 months+8.21%
Current year+7.25%
1 week 37.2
Extreme 37.2
38.89
1 month 32.41
Extreme 32.41
38.89
Current year 27.68
Extreme 27.68
41
1 year 13.45
Extreme 13.45
41
3 years 7.33
Extreme 7.33
41
5 years 7.33
Extreme 7.33
41
10 years 1.75
Extreme 1.75
41
Date Insider Type Main position Quantity % Market Cap.
06-07Sell

Chief Financial Officer

-36,000 0.0295%
05-12Free

Director

6,518 0.0053%
05-12Free

Chairman

10,430 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%+2.30%+176.24%+68.99% 4.69B
-2.41%+0.14%+39.53%+154.43% 1,010B
+1.07%+3.48%+53.75%+50.64% 580B
+1.32%+0.22%+18.35%+65.35% 402B
+0.77%0.00%+19.99%+16.80% 330B
-1.42%-1.44%+45.50%+8.37% 294B
-0.85%-2.86%+22.05%+13.80% 280B
+0.44%+3.48%+24.48%+34.39% 281B
+1.66%+1.20%-44.67%-47.49% 197B
+0.32%+1.61%+19.48%+63.42% 192B
Average -0.16%+1.12%+37.47%+42.87% 357.17B
Weighted average by Cap. -0.80%+1.00%+30.03%+66.17%

Financials

2026 *2027 *
Net sales 1.26B 1.09B 1B 937M 1.76B 120B 1.78B 11.82B 4.61B 58.2B 4.72B 4.62B 202B 1.29B 1.11B 1.02B 959M 1.8B 122B 1.83B 12.1B 4.72B 59.56B 4.83B 4.73B 206B
Net income 414M 358M 330M 309M 579M 39.4B 588M 3.9B 1.52B 19.18B 1.56B 1.52B 66.39B 455M 393M 362M 339M 635M 43.24B 645M 4.28B 1.67B 21.05B 1.71B 1.67B 72.87B
Net Debt 54.5M 47.07M 43.38M 40.6M 76.09M 5.18B 77.27M 512M 200M 2.52B 205M 200M 8.73B -403M -348M -321M -301M -563M -38.34B -572M -3.79B -1.48B -18.66B -1.51B -1.48B -64.62B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
833
Date Price Change Volume
26-06-12 38.48 $ +0.92% 627,573
26-06-11 38.13 $ +0.11% 1,840,258
26-06-10 38.09 $ -0.44% 2,103,588
26-06-09 38.26 $ +2.33% 1,639,223
26-06-08 37.39 $ -0.60% 1,152,799
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
38.48USD
Average target price
51.50USD
Spread / Average Target
+33.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INDV Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!